A Phase 2 interventional study of CTP-543 and CTP-543 Matching Placebo in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 10 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-12-09.
Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 10th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 2, and was the 2nd registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:
Sun Pharma Japan Limited · Sites in Japan
Ages 18–65
Sun Pharmaceutical Industries, Inc. · Sites in United States, Canada
Ages 12–17
By country, each count listing its studies:
Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6
First in 2017; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 336 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Concert Pharmaceuticals, one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited: 2 open now, 3 under way, 3 of them phase 3. Of 7 finished, 7 (100%) have results posted.
Among the 10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited, this one is the 10th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 2, and was the 2nd registered.
Sun Pharmaceutical Industries Limited’s Alopecia Areata studies by the year they started, since 2017.
1 of the studies testing deuruxolitinib in Alopecia Areata that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sun Pharmaceutical Industries Limited’s 10 in Alopecia Areata:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1 x 8 mg CTP-543 tablet and 1 x CTP-543 matching placebo tablet, twice daily (BID) for 24 weeks.
Drug: CTP-543 · Drug: CTP-543 Matching Placebo
Participants received 16 mg (2 x 8 mg) CTP-543 tablets, once daily (QD) and after 12 hours, received 2 x CTP-543 matching placebo tablets, QD for 24 weeks.
Drug: CTP-543 · Drug: CTP-543 Matching Placebo
CTP-543 administered as 8 mg tablet.
Administered as tablets to aid treatment masking.
Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).
Time frame: Baseline, Week 24
Percentage of Participants Achieving at Least a 90%, 75%, and 50% Relative Reduction in SALT Score From Baseline
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Percentage of participants achieving at least a 50%, 75%, 90% relative reduction in SALT score from baseline at Weeks 4, 8, 12, 16, 20, and 24 are reported.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Absolute Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Absolute change equals the difference in SALT measurements (baseline SALT score - follow-up SALT score).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16 and 20
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).
Time frame: Baseline, Weeks 4, 8, 12, 16 and 20
Percentage of Participants With Change in Satisfaction of Hair Coverage
Participant satisfaction question was used to assess overall satisfaction with hair coverage, with responses ranging from 1 to 5, as follows: 1 (very dissatisfied), 2 (dissatisfied), 3 (somewhat satisfied), 4 (mostly satisfied), 5 (very satisfied). Higher scores indicate better satisfaction with hair coverage. The percentage of participants with change from Baseline to the Week 24 satisfaction level was reported as categories: satisfied to satisfied; satisfied to dissatisfied; dissatisfied to satisfied and dissatisfied to dissatisfied. Data is reported only for participants with change from Baseline in satisfaction level.
Time frame: Baseline, Week 24
Number of Participants With Adverse Events as a Measure of Safety
Time frame: 24 Weeks
Participants were enrolled at 10 study centers in the United States from 21 March 2019 to 21 November 2019.
| Milestone | CTP-543 8 mg BID | CTP-543 16 mg QD |
|---|---|---|
| Started | 29 | 28 |
| Safety population | 29 | 28 |
| Completed | 25 | 26 |
| Not completed | 4 | 2 |
| Withdrew: Withdrew consent | 4 | 2 |
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).
| percent change | CTP-543 8 mg BID | CTP-543 16 mg QD |
|---|---|---|
| Relative Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 | 46.4 ± 38.21 | 18.0 ± 32.32 |
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Percentage of participants achieving at least a 50%, 75%, 90% relative reduction in SALT score from baseline at Weeks 4, 8, 12, 16, 20, and 24 are reported.
| Percentage of participants | CTP-543 8 mg BID | CTP-543 16 mg QD |
|---|---|---|
| 90% Reduction: Week 4 | 0 (0 to 1.7) | 0 (0 to 1.8) |
| 90% Reduction: Week 8 | 0 (0 to 1.7) | 0 (0 to 1.8) |
| 90% Reduction: Week 12 | 3.4 (0 to 10.7) | 0 (0 to 1.8) |
| 90% Reduction: Week 16 | 6.9 (0 to 16.4) | 0 (0 to 1.8) |
| 90% Reduction: Week 20 | 13.8 (1.5 to 26.0) | 0 (0 to 1.8) |
| 90% Reduction: Week 24 | 20.7 (6.6 to 34.8) | 3.6 (0 to 11.1) |
| 75% Reduction: Week 4 | 0 (0 to 1.7) | 0 (0 to 1.8) |
| 75% Reduction: Week 8 | 3.4 (0 to 10.7) | 3.6 (0 to 11.1) |
| 75% Reduction: Week 12 | 6.9 (0 to 16.4) | 0 (0 to 1.8) |
| 75% Reduction: Week 16 | 20.7 (6.6 to 34.8) | 3.6 (0 to 11.1) |
| 75% Reduction: Week 20 | 31.0 (15.2 to 46.9) | 10.7 (0 to 22.1) |
| 75% Reduction: Week 24 | 31.0 (15.2 to 46.9) | 10.7 (0 to 22.1) |
| 50% Reduction: Week 4 | 0 (0 to 1.7) | 0 (0 to 1.8) |
| 50% Reduction: Week 8 | 6.9 (0 to 16.4) | 3.6 (0 to 11.1) |
| 50% Reduction: Week 12 | 24.1 (9.3 to 38.9) | 7.1 (0 to 16.9) |
| 50% Reduction: Week 16 | 34.5 (18.2 to 50.7) | 14.3 (1.6 to 26.9) |
| 50% Reduction: Week 20 | 41.4 (24.6 to 58.1) | 14.3 (1.6 to 26.9) |
| 50% Reduction: Week 24 | 48.3 (31.3 to 65.3) | 17.9 (4.2 to 31.5) |
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Absolute change equals the difference in SALT measurements (baseline SALT score - follow-up SALT score).
| Score on a scale | CTP-543 8 mg BID | CTP-543 16 mg QD |
|---|---|---|
| Change from Baseline at Week 4 | 0.8 ± 6.92 | -0.8 ± 4.49 |
| Change from Baseline at Week 8 | 6.5 ± 15.02 | 2.1 ± 11.93 |
| Change from Baseline at Week 12 | 18.5 ± 23.27 | 5.3 ± 19.48 |
| Change from Baseline at Week 16 | 27.0 ± 29.31 | 9.4 ± 25.46 |
| Change from Baseline at Week 20 | 32.8 ± 29.25 | 13.4 ± 28.06 |
| Change from Baseline at Week 24 | 37.7 ± 30.75 | 15.7 ± 28.25 |
The SALT is a quantitative assessment of scalp hair loss. SALT scores range in severity from 0 (no hair loss) to a maximum of 100 (complete hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[baseline SALT score - follow-up SALT score\]/baseline SALT score).
| percent change | CTP-543 8 mg BID | CTP-543 16 mg QD |
|---|---|---|
| Change from Baseline at Week 4 | 1.4 ± 9.67 | -1.3 ± 7.26 |
| Change from Baseline at Week 8 | 8.6 ± 20.58 | 2.7 ± 19.43 |
| Change from Baseline at Week 12 | 23.7 ± 31.25 | 5.1 ± 22.91 |
| Change from Baseline at Week 16 | 33.3 ± 35.90 | 9.4 ± 28.85 |
| Change from Baseline at Week 20 | 40.6 ± 36.85 | 14.8 ± 31.26 |
Participant satisfaction question was used to assess overall satisfaction with hair coverage, with responses ranging from 1 to 5, as follows: 1 (very dissatisfied), 2 (dissatisfied), 3 (somewhat satisfied), 4 (mostly satisfied), 5 (very satisfied). Higher scores indicate better satisfaction with hair coverage. The percentage of participants with change from Baseline to the Week 24 satisfaction level was reported as categories: satisfied to satisfied; satisfied to dissatisfied; dissatisfied to satisfied and dissatisfied to dissatisfied. Data is reported only for participants with change from Baseline in satisfaction level.
| Percentage of participants | CTP-543 8 mg BID | CTP-543 16 mg QD |
|---|---|---|
| Satisfied to Satisfied | 0 | 3.6 |
| Satisfied to Dissatisfied | 3.4 | 0 |
| Dissatisfied to Satisfied | 55.2 | 17.9 |
| Dissatisfied to Dissatisfied | 34.5 | 75.0 |
Results for this outcome have not been posted.
Collected over Adverse Events: From first dose of study drug up to Week 28; All-cause mortality: Randomization up to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CTP-543 8 mg BID | 0/29 (0%) | 0/29 (0%) | 23/29 (79.3%) |
| CTP-543 16 mg QD | 0/28 (0%) | 0/28 (0%) | 23/28 (82.1%) |
| Event | CTP-543 8 mg BID | CTP-543 16 mg QD |
|---|---|---|
| HeadacheNervous system disorders | 8/29 | 5/28 |
| NasopharyngitisInfections and infestations | 5/29 | 5/28 |
| Upper respiratory tract infectionInfections and infestations | 5/29 | 3/28 |
| AcneSkin and subcutaneous tissue disorders | 4/29 | 4/28 |
| Weight increasedInvestigations | 1/29 | 3/28 |
| ConstipationGastrointestinal disorders | 3/29 | 1/28 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/29 | 2/28 |
| FallInjury, poisoning and procedural complications | 0/29 | 2/28 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 0/29 | 2/28 |
| Increased tendency to bruiseBlood and lymphatic system disorders | 0/29 | 2/28 |
Randomized Population included all the randomized participants.
| Age, Continuous(years) | CTP-543 8 mg BID | CTP-543 16 mg QD | Total |
|---|---|---|---|
| Mean | 40.4 ± 12.98 | 39.8 ± 13.65 | 40.1 ± 13.20 |
| Sex: Female, Male(Participants) | CTP-543 8 mg BID | CTP-543 16 mg QD | Total |
|---|---|---|---|
| Female | 20 | 18 | 38 |
| Male | 9 | 10 | 19 |
| Ethnicity (NIH/OMB)(Participants) | CTP-543 8 mg BID | CTP-543 16 mg QD | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 26 | 24 | 50 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | CTP-543 8 mg BID | CTP-543 16 mg QD | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 |
| Race — Asian | 2 | 1 | 3 |
| Race — Black or African American | 0 | 3 | 3 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Race — White | 27 | 23 | 50 |
| Race — Other | 0 | 1 | 1 |
| Region of Enrollment(participants) | CTP-543 8 mg BID | CTP-543 16 mg QD | Total |
|---|---|---|---|
| United States | 29 | 28 | 57 |
| Severity of Alopecia Tool (SALT) Score(score on a scale) | CTP-543 8 mg BID | CTP-543 16 mg QD | Total |
|---|---|---|---|
| Mean | 87.1 ± 17.23 | 90.4 ± 17.46 | 88.7 ± 17.27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Nov 2019, 8 months.
Results were first posted in Dec 2022, 3 years after primary completion. A results delay was requested in Nov 2020.
Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deuruxolitinib